Modality
Degrader
MOA
BiTE
Target
Menin
Pathway
Incretin
SMA
Development Pipeline
Preclinical
~Dec 2011
→ ~Mar 2013
Phase 1
~Jun 2013
→ ~Sep 2014
Phase 2
~Dec 2014
→ ~Mar 2016
Phase 3
~Jun 2016
→ ~Sep 2017
NDA/BLA
Dec 2017
→ Jan 2027
NDA/BLACurrent
NCT07117451
595 pts·SMA
2019-08→2025-11·Active
NCT03419025
2,503 pts·SMA
2017-12→2027-01·Completed
3,098 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-11-135mo agoPh3 Readout· SMA
2027-01-1810mo awayPh3 Readout· SMA
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
NDA/BLA
Complet…
NDA/BLA
Active
Catalysts
Ph3 Readout
2025-11-13 · 5mo ago
SMA
Ph3 Readout
2027-01-18 · 10mo away
SMA
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Zanutinib | Bristol-Myers Squibb | Phase 2/3 | APOC3 | |
| Bemarelsin | Daiichi Sankyo | Preclinical | GLP-1R | |
| DSN-7360 | Daiichi Sankyo | Approved | SGLT2 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| BII-8315 | Biogen | NDA/BLA | CDK2 | |
| Geliglumide | Samsung Biologics | Phase 1 | Aβ |